Last week, Hengrui Pharmaceuticals announced a licensing agreement with Merck KGaA for its next-generation potent and selective poly (ADP-ribose) polymerase 1 (PARP1) inhibitor, HRS-1167. RNAi drugmaker Argo Biopharma recently completed a Pre-A+ financing round worth $40.97 million. The key investors included China Investment, Huagai Capital, Yuanxihaihe Fund, and Trinity Fund, an existing shareholder.